LATEST

FDA approves rare liver disease drugFDA recently granted accelerated approval for obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) for the treatment of primary biliary cholangitis.
New kidney warning on popular diabetes drugsSoon after FDA warned about a potential increased risk of foot and leg amputations with the use of the type 2 diabetes medication canagliflozin (Invokana and Invokamet, Janssen Biotech), the agency strengthened the existing warning about the risk of acute kidney injury with Invokana and Invokamet, as well as dapagliflozin (Farxiga and Xigduo XR, AstraZeneca).
Teva halts migraine patch sales over burnsTeva Pharmaceuticals is temporarily suspending sales and distribution of its sumatriptan iontophoretic transdermal system (Zecuity) patch for migraines, after FDA said it is investigating the risk of serious burns with the use of the patch.
FDA warns about OTC antacids, antidiarrheal medFDA is warning consumers about the risk of serious bleeding when using over-the-counter aspirin-containing antacid products to treat heartburn. The agency also issued a separate warning about loperamide (Imodium, Johnson & Johnson), saying that abuse or misuse of the product can cause serious heart problems that can lead to death.
Top 5 facts about cancer drug costsThe global oncology market was worth $107 billion in 2015, and global annual cancer drug costs surged by 11.5% from 2011 to 2015, according to a new report.
Pharma company keeps pace with rise of diabetesNovo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.
3 ways to improve diabetes med adherenceA systemic review highlights studies that improved medication adherence and patient outcomes using strategies that could be effective if employed in real-world healthcare settings.

Poll

View Results